A5074627346- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gallbladder and Bile Duct Disorders
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Colorectal Cancer Treatments and Studies
- Hepatitis B Virus Studies
- Cell death mechanisms and regulation
- Neuroendocrine Tumor Research Advances
- Cancer Mechanisms and Therapy
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Liver physiology and pathology
- Cardiovascular Function and Risk Factors
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Curcumin's Biomedical Applications
- Immune Cell Function and Interaction
- Pancreatitis Pathology and Treatment
- RNA modifications and cancer
- Mitochondrial Function and Pathology
- Esophageal Cancer Research and Treatment
Saitama Cancer Center
2016-2025
Kyoto Medical Center
2019-2024
University of Shizuoka
2018-2024
Fukuoka University Hospital
2023
National Disaster Medical Center
2018-2023
Japan Clinical Cancer Research Organization
2008-2022
Nikon (United States)
2021
Nihon University
2021
Hachinohe Gakuin University
2021
Fukuda Denshi (Japan)
2021
Abstract Multikinase inhibitor sorafenib inhibits proliferation and angiogenesis of tumors by suppressing the Raf/MEK/ERK signaling pathway VEGF receptor tyrosine kinase. It significantly prolongs median survival patients with advanced hepatocellular carcinoma (HCC) but response is disease‐stabilizing cytostatic rather than one tumor regression. To examine mechanisms underlying relative resistance in HCC, we investigated role autophagy, an evolutionarily conserved self‐digestion pathway,...
Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, tyrosine kinases are involved in tumor‐cell signal transduction tumor angiogenesis. This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, preliminary efficacy of sorafenib Japanese patients with hepatocellular carcinoma (HCC) underlying liver dysfunction. Patients unresectable HCC, Child–Pugh status A or B, adequate organ functions were treated. single dose administered, followed...
The tumor suppressor p53 has been implicated in the pathogenesis of non-cancer-related conditions such as insulin resistance, cardiac failure, and early aging. In addition, accumulation observed hepatocytes individuals with fibrotic liver diseases, but significance this is not known. Herein, we have mechanistically linked activation to fibrosis. Hepatocyte-specific deletion mice gene encoding Mdm2, a protein that promotes degradation, led hepatocyte synthesis connective tissue growth factor...
Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) Sor treatment HCC.We multicenter open-labeled randomized phase II in chemo-naïve patients HCC Child-Pugh scores 5-7. Eligible were randomly assigned 2:1 receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m2, day 1, every 4-6 weeks) or (400 bid). The primary end point...
With this study, we sought to characterise the impact of pro-inflammatory cytokines on outcomes gemcitabine monotherapy (GEM) in patients with pancreatic cancer (PC). Treatment-naive advanced PC and no obvious infections were eligible for enrolment. All scheduled undergo systemic chemotherapy. Serum measured using an electro-chemiluminescence assay method before High cytokine levels defined as values greater than median. Clinical data collected prospectively. Sixty who received GEM included...
Tumor cells are characterized by uncontrolled proliferation, often driven activation of oncogenes, and apoptosis resistance. The oncogenic kinase inhibitor sorafenib can significantly prolong median survival patients with advanced hepatocellular carcinoma (HCC), although the response is disease-stabilizing cytostatic rather than one tumor regression. Bcl-xL (B cell lymphoma extra large), an antiapoptotic member B lymphoma-2 (Bcl-2) family, frequently overexpressed in HCC. Here, we present...
Abstract Background Biliary tract cancer (BTC) has a poor prognosis and lacks standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast receptor (FGFR) 4, platelet-derived (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a known inhibitor of VEGF receptors 1–3, FGFRs 1–4, PDGFR-α) was evaluated for treatment Methods In this single-arm, multicenter, open-label, phase 2 study, patients with BTC received 24 mg orally once daily 28-day cycles. The primary...
Etoposide plus cisplatin (EP) and irinotecan (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC).To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) patients with NEC the digestive system.This open-label phase 3 randomized clinical trial enrolled chemotherapy-naive aged 20 to 75 years who had recurrent unresectable (according 2010 World Health Organization classification system) arising from gastrointestinal...
<b><i>Introduction:</i></b> Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher activity is expected for the combination treatment. The aim of this trial was to evaluate efficacy safety in HAIC using patients HCC. <b><i>Methods:</i></b> In multicenter, open-labeled, single-arm, phase II trial, HCC categorized as Child-Pugh class A...
Abstract Protein arginine methyltransferase 5 (PRMT5) is a well-known epigenetic regulatory enzyme. However, the role of PRMT5-mediated methylation in gene transcription related to cardiac fibrosis unknown. Here we show that fibroblast-specific deletion PRMT5 significantly reduces pressure overload-induced and improves dysfunction male mice. Both PRMT5-selective inhibitor EPZ015666 knockdown suppress α-smooth muscle actin (α-SMA) expression induced by transforming growth factor-β (TGF-β)...
Anti-apoptotic members of the Bcl-2 family, including Bcl-2, Bcl-xL, Mcl-1, Bcl-w and Bfl-1, inhibit mitochondrial pathway apoptosis. Bcl-xL Mcl-1 are constitutively expressed in liver. Although previous research established as a critical apoptosis antagonist differentiated hepatocytes, significance liver, especially conjunction with has not been clear. To examine this question, we generated hepatocyte-specific Mcl-1–deficient mice by crossing mcl-1 flox / AlbCre further crossed them bcl-x...
High serum level of interleukin 6 (IL-6) is associated with high degree tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration clinical characteristics in patients IL-6 level. However, IL-6-related factors treatment-naive advanced pancreatic cancer (PC) have not been established. The goal this study was to identify PC who were scheduled undergo first-line chemotherapy.Patients eligible for inclusion study. Patients did receive chemotherapy excluded....
The transcription factor nuclear factor-κB (NF-κB) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth 2 (IGF2) is a key target of NF-κB activated by HER2/HER3 signaling to form tumor spheres in breast cells. IGF2 receptor, IGF1 R, was expressed at high levels CSC-enriched populations primary Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) induced expression stemness factor, inhibitor...
Abstract Background Fibroblast growth factor receptor 2 ( FGFR2 ) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer (BTC). However, efficient detection and the exact frequency of rearrangements among patients with BTC have not been determined, clinical characteristics rearrangement-positive fully elucidated. We aimed determine those elucidate their clinicopathological characteristics. Methods Paraffin-embedded tumor samples from...
Abstract Background In the NAPOLI‐1 phase 3 trial, liposomal irinotecan (nal‐IRI) +5‐fluorouracil/leucovorin (5‐FU/LV) significantly increased mPFS versus 5‐FU/LV (3.1 vs. 1.5 months [unstratified HR = 0.56, p 0.0001]) in patients with mPAC that progressed on prior gemcitabine‐based therapy. This randomized 2 trial evaluated nal‐IRI+5‐FU/LV tolerability (Part 1), safety, and efficacy 2; outcomes reported here) Japanese Methods Patients were 1:1 stratified by KPS (70 80 ≥90) baseline albumin...